GENITOURINARY CANCERS

In findings from the phase III PROSPER trial released ahead of the 2018 Genitourinary Cancers Symposium, the enzalutamide (Xtandi) and androgen deprivation therapy (ADT) combination reduced the risk of metastases or death by 71% compared with ADT alone for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).

As stated in findings from IMmotion151, a phase III open-label study, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) induced a 26% reduction in the risk of progression or death compared with sunitinib (Sutent) for patients with untreated PD-L1–positive metastatic renal cell carcinoma. This study was released ahead of the 2018 Genitourinary Cancers Symposium.

The combination of abiraterone acetate in combination with prednisone and androgen deprivation therapy has been approved by the FDA as a treatment for men with high-risk castration-sensitive prostate cancer.

Treatment with cabozantinib induced similar quality of life results as treatment with everolimus in patients with advanced renal cell carcinoma, according to results of the randomized, open-label, international phase III METEOR trial.

Circulating tumor cell conversion and CTC value &ge; 1 at baseline were superior predictors of overall survival than PSA in men with metastatic castration-resistant prostate cancer, according to an analysis of results from 5 clinical trials.<br /> &nbsp;

Charles J. Ryan, MD, will soon be joining the University of Minnesota Medical School as director of the Hematology, Oncology, and Transplantation Division in the Department of Medicine, effective April 2018.

David F. McDermott, MD,&nbsp;shares some of the successes with immunotherapy in RCC and gave his insight on the future treatment of these patients.

Rana R. McKay, MD,&nbsp;discusses the evolving management of patients with advanced RCC, specifically the future of combinations with immunotherapy regimens.

According to results of a subgroup analysis of the phase III METEOR trial, cabozantinib (Cabometyx) demonstrated a 4.7 month improvement in progression-free survival compared with everolimus&nbsp;(Afinitor)&nbsp;in pretreated patients with advanced renal cell carcinoma with bone metastases at baseline.

According to results from the phase I JAVELIN Solid Tumor study recently published in the Lancet Oncology, the PD-L1 inhibitor avelumab (Bavencio) induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.<br /> &#8203;

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of&nbsp;medicine and&nbsp;urology, Mount Sinai School of Medicine, discusses the use of abiraterone and docetaxel in patients with&nbsp;metastatic castration-resistant prostate cancer.&nbsp;

Prachi Mishra, PhD, was awarded the first &ldquo;Colonel (Ret.) David G. McLeod Prostate Cancer Translational Research Fellowship&rdquo; at the Uniformed Services University of Health Sciences on December 7. She was presented this award in front of Department of Defense leadership, industry leaders, cancer scientists, military healthcare providers, and other colleagues.

Pembrolizumab (Keytruda) has been approved in Japan for the treatment&nbsp;of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor.

Based on results of the Ib/II Study 111, the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib has been granted a breakthrough therapy designation by the FDA for the treatment of patients with advanced and/or metastatic renal cell carcinoma.

Arjun Balar, MD,&nbsp;discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.

With genetic screening for mutations and biomarkers gaining more prevalence in diagnosing and treating cancer, genetic testing and counseling for patients with prostate cancer is becoming a pressing concept that urologists need to better understand. At the 2017 LUGPA Annual Meeting, Leonard Gomella, MD, gave a presentation stressing the importance of integrating genetic testing into clinical practice.

Determining the sequence of therapies has yet to be wholly standardized for treating castration-resistant prostate cancer (CRPC), particularly in the case of abiraterone (Zytiga) and enzalutamide (Xtandi).

Therapeutic Management of Nonmetastatic Prostate Cancer

Therapeutic Approach for Nonmetastatic Prostate Cancer

The PD-L1 inhibitor avelumab (Bavencio) has been granted a breakthrough therapy designation by the FDA&nbsp;for use in combination with the VEGF inhibitor axitinib (Inlyta) in treatment-na&iuml;ve patients with advanced renal cell carcinoma.